Patents by Inventor Laura FERRAIUOLO

Laura FERRAIUOLO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240060960
    Abstract: The disclosure provides for methods of predicting disease progression comprising detecting a modification of one or more disease markers in a glial cell or neuronal cell generated from a skin cell of the subject. The disclosed methods include methods of identifying subjects that are responsive to a therapeutic agent and methods of determining effectiveness of a therapeutic agent.
    Type: Application
    Filed: January 13, 2022
    Publication date: February 22, 2024
    Applicants: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, THE UNIVERSITY OF SHEFFIELD
    Inventors: Kathrin Christine Meyer, Cassandra Nicole Dennys-Rivers, Laura Ferraiuolo
  • Publication number: 20220265635
    Abstract: The invention is directed to 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding, heat shock factor 1 pathways, or nuclear erythroid 2-related factor 2 pathways.
    Type: Application
    Filed: October 18, 2019
    Publication date: August 25, 2022
    Inventors: Richard James Mead, Pamela Jean Shaw, Claude Ogoe, Ning Shan, Laura Ferraiuolo
  • Publication number: 20210353613
    Abstract: The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H- dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding of Cu/Zn Superoxide Dismutase (SOD1) or mediated by astrocyte toxicity affecting motor neuron survival.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 18, 2021
    Inventors: Ning Shan, Pamela Jean Shaw, Claude Ogoe, Laura Ferraiuolo
  • Publication number: 20180263992
    Abstract: Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the methods. The methods comprise inhibiting EGFR signalling, and inhibiting MyD88-dependent TLR/IL-R1 signalling, in the central nervous system of a subject in need of such prevention or treatment. The compositions comprise an inhibitor of EGFR signalling, and an inhibitor of MyD88-dependent TLR/IL-R1 signalling.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 20, 2018
    Inventors: Peter RICHARDSON, Richard MEAD, Laura FERRAIUOLO, Kenneth Patrick MULVANY